Yes 3/4 of it is positive but that missing piece of not...

Yes 3/4 of it is positive but that missing piece of not achieving “The primary endpoint of reduction in inflammatory lesions did not achieve statistical significance.” This part is what may hurt BOT. Had they achieved success in this and provided a IGA success score of 13.8+ then it wouldn’t be an issue.

Given the statement of not achieving key statistical significance was somewhat hidden in the body of the announcement also provide further evidence its not that positive hence Phase 3 immediately.

In saying this, IHL hopefully learns a lot from BOT results albeit not related one bit in terms of acne but does have a similar path.

The IP comes into play absolutely but it’s the success of the first trial that will set the company apart which in turn will elevate the lucrative benefits of the IP.